RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Proprieta’ strutturali e attivita’ funzionale di un complesso proteico modificante la cromatina nell’uomo
• 2 - Enzimologia strutturale di proteine coinvolte nella biosintesi del NAD
• 3 - BERSAGLI MOLECOLARI PER NUOVE TERAPIE ANTINEOPLASTICHE ATTRAVERSO LO STUDIO DI PROTEINE-SEGNALE CELLULARI E VIRALI E DI INIBITORI SPECIFICI
• 4 - Enzimi dipendenti dal piridossale 5'-fosfato. Aspetti strutturali, funzionali e biomedici.
• 5 - Regolazione della maturazione proteolitica del precursore del peptide beta-amiloide dell'Alzheimer
• 6 - Mitocondri e morte cellulare: identificazione di nuovi bersagli terapeutici
• 7 - Sintesi stereoselettiva e valutazione biologica di composti mirati all'attività antivirale
• 8 - Caratterizzazione strutturale e funzionale del trasportatore umano degli amminoacidi eccitatori di tipo 2 (EAAT2) e della sua interazione con nuovi ligandi di interesse farmaceutico
• 9 - Fattori oncogenici ed oncosoppressori nei tumori del sistema nervoso: meccanismi di azione ed identificazione di nuove molecole regolatorie.
• 10 - Progettazione, sintesi, caratterizzazione e sviluppo di nuovi inibitori delle deacetilasi istoniche con potenziali attività traslazionali per il trattamento delle leucemie mieloidi acute

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze chimiche
  • CHIMICA ORGANICA
• Area scientifico disciplinare: Scienze biologiche
  • BIOCHIMICA
  • BIOLOGIA MOLECOLARE
• Area scientifico disciplinare: Scienze mediche

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)
  • CRYSTAL GROWTH (separation by crystallisation in general B01D9/00)
    • SINGLE-CRYSTAL-GROWTH (by using ultra-high pressure, e.g. for the formation of diamonds B01J3/06); UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL (zone-refining of metals or alloys C22B); PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE (casting of metals, casting of other substances by the same processes or devices B22D; working of plastics B29; modifying the physical structure of metals or alloys C21D, C22F); SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE (for producing semiconductor devices or parts thereof H01L); APPARATUS THEREFOR
  • ORGANIC CHEMISTRY (such compounds as the oxides, sulfides, or oxysulfides of carbon, cyanogen, phosgene, hydrocyanic acid or salts thereof C01; products obtained from layered base-exchange silicates by ion-exchange with organic compounds such as ammonium, phosphonium or sulfonium compounds or by intercalation of organic compounds C01B33/44; macromolecular compounds C08; dyes C09; fermentation products C12; fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture C12P; production of organic compounds by electrolysis or electrophoresis C25B3/00, C25B7/00)
    • PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

Classificazione geografica

• Regione: Veneto

Bibliografia

1. Cohen, P. (2002) Protein kinases – the major drug targets of the twenty-first century?. Nature Rev. 1, 309-315.
2. Blume-Jensen P. and Hunter, T (2001) Oncogenic kinase signalling, Nature 411, 355-365.
3. Carroll, M., Ohno-Jones, S., Tamura, S., Buchdunger, E., Zimmermann,J., Lydon, N. B., Gilliland, D. G., Druker, B. J. (1997) CGP 57148, a Tyrosine Kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90, 4947-4952.
4. Meggio, F., and Pinna, L.A. (2003) One-thousand-and-one substrates of protein kinase CK2? FASEB J. 17, 349-368.
5. Guerra B. and Issinger O-G. (1999) Protein kinase CK2 and its role in cellular proliferation, development and pathology, Electrophoresis 20, 391-408.
6. Landesman-Bollag R., Channavajhala P.L., Cardif R.D. and Seldin D.C. (1998) p53 deficiency and misexpression of protein kinase CK2alpha collaborate in the development of thymic limphomas in mice. Oncogene 16, 2965-2974.
7. Orlandini M., Semplici F., Ferruzzi R., Meggio F., Pinna L.A. and Oliviero S. (1998) Protein kinase CK2alpha’ is induced by serum as a delayed early gene and cooperates with Ha-ras in fibroblast transformation. J. Biol. Chem. 273, 21292-21297.
8. Li D., Dobrowolska G., Aicher L.D., Chen M., Wright J.H., Drueckes P., Dunphy R.L., Munar E.S. and Krebs E.G. (1999) Expression of the casein kinase 2 subunits in Chinese hamster ovary and 3T3 L1 cells provides information on the role of the enzyme in cell proliferation and cell cycle. J. Biol. Chem. 274, 32988-32996.
9. Guo C., Yu S., Wang H., Davis A.T., Green J.E. and Ahmed K. (2000) A potential role of nuclear matrix-associated protein kinase CK2 in protection against drug-induced apoptosis in cancer cells. J. Biol. Chem. 276, 5992-5999.
10. Ruzzene M., Penzo D. and Pinna L.A. (2002) Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase dependent degradation of HS1 protein in Jurkat cells. Biochem J. 364, 41-47.
11. Ahmed, K., Gerber, D.A. and Cochet, C. (2002) Joining the cell survival squad: an emerging role for protein kinase CK2. Trends Cell Biol. 12, 226-230.
12. Tawfic S., Yu S., Wang R., Faust R., Davis A. and Ahmed K. (2001) Protein kinase CK2 signal in neoplasia. Histol. & Histopathol. 16, 573-582.
13. Mishra, S., Reichert, A., Cunnick, J., Senadheera, D., Hemmeryckx, B., Heisterkamp, N. and Groffen, J. (2003) Protein kinase CKII alpha interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cells. Oncogene 22, 8255-8262.
14. S. Sarno, P. Vaglio, F. Meggio, O-G. Issinger and L.A. Pinna "Protein kinase CK2 mutants defective in substrate recognition: purification and kinetic analysis" (1996) J. Biol. Chem. 271, 10595-10601
15. S. Sarno, P. Vaglio, O. Marin, O-G. Issinger, K. Ruffato and L.A. Pinna "Mutational analysis of residues implicated in the interaction between protein kinase CK2 and peptide substrates" (1997) Biochemistry, 36, 11717-11724
16. K. Niefind, B. Guerra, L.A. Pinna, O-G. Issinger and D. Schomburg "Crystal structure of the catalytic subunit of protein kinase CK2 from Zhea mays at 2.1 resolution (1998) EMBO J. 17, 2451-2462
17. K. Niefind, B. Guerra, I. Ermakowa and O-G. Issinger "Crystal structure of human protein kinase CK2: insights into basic properties of the CK2 holoenzyme" (2001) EMBO J. 20, 5320-5331.
18. R. Battistutta, S. Sarno, E. De Moliner, E. Papinutto, G. Zanotti and L.A. Pinna "The replacement of ATP by the competitive ininbitor emodin induces conformational modifications in the catalytic site of protein kinase CK2" (2000) J. Biol. Chem. 275, 29618-29622.
19. R. Battistutta E. DeMoliner, S. Sarno, G. Zanotti and L.A. Pinna "Structural features underlying selective inhibition of protein kinase CK2 by ATP site-directed tetrabromo-benzotriazole" (2001) Protein Science, 10, 2200-22.
20. Sarno, S., et al. (2003) Biochemical and 3D-structural data on the specific inhibition of protein kinase CK2 by (5-oxo-5,6-dihydro-indolo(1,2-a)quinazolin-7-yl)acetic acid (IQA). Biochem. J. 374, 639-646.
21. De Moliner, E., Moro, S., Sarno, S., Zagotto, G., Zanotti, G., Pinna, L.A., and Battistutta, R. (2003) Inhibition of protein kinase CK2 by anthraquinone-related compounds. A structural insight. J. Biol. Chem. 278, 1831-1836.
22. S. Sarno, H. Reddy, F. Meggio, M. Ruzzene,, Davies S.P., Donella-Deana A., Shugar D. and Pinna L.A. Selectivity of 4,5,6,7-tetrabromo-benzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ("casein kinase-2") (2001) FEBS Lett. (2001) 496, 44-48.
23. Gross, S.D. and Anderson, R.A.: “Casein kinase I: spatial organization and positioning of a multifunctional protein kinase family“ (1998) Cell Signaling 10, 699-711.
24. Peters, J.M., McKay, R.M., McKay, J.P. and Graff, J.M.: “Casein kinase I transduces Wnt signals” (1999) Nature 401, 345-350.
25. Marin, O., Bustos, V.H., Cesaro, L., Meggio, F., Pagano, M.A., Antonelli, M., Allende, C.C., Pinna, L.A. and Allende, J.E. (2003) A noncanonical sequence phosphorylated by casein kinase 1 in beta-catenin may play a role in casein kinase 1 targeting of important signalling proteins. Proc. Natl. Acad. Sci. USA 100, 10193-10200.
26. Liu, C., Li, Y., Semenov, M., Han, C., Baeg, G.-H., Tan, Y., Zhang, Z., Lin, X., and He, X.: “Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism” (2002) Cell 108, 837-847.
27. Marin, O., Burzio, V., Boschetti, M., Meggio, F., Allende, C.C., Allende, J.E. and Pinna, L.A. (2002) Structural features underlying the multisite phosphorylation of the A domain of the NF-AT4 transcription factor by protein kinase CK1. Biochemistry 41, 618-627.
28. Longenecker, K.L., Roach, P.J. and Hurley, T.D. (1996) Three-dimensional structure of mammalian casein kinase I: molecular basis for phosphate recognition. J. Mol. Biol. 257, 618-631.
29. Xu, R.M., Carmel, G., Sweet, R.M., Kuret, J. and Cheng X. (1995) Crystal structure of casein kinase-1, a phosphate-directed protein kinase.EMBO J. 14, 1015-1023.
30. Rabbitts T.H. (1994) Chromosomal translocations in human cancer. Nature, 372: 143-149.
31. Heisterkamp, N., Stam, K., Groffen, J., de Klein, A., and Groffen, G. (1985) Structural organization of the bcr gene and its role in the Ph1 translocation. Nature, 315: 758-761.
32. Talpaz, M., et al. (2002) Glivec™ (Imatinib mesylate) induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase II study. Blood 99, 1928-1936.
33. Kantarjian, H.M., et al. (2002) Gleevec™ (imatinib mesylate) induces hematologic and cytogenetic responses in the majority of patients with chronic myeloid leukemia in chronic phase: results of a phase II study. New Engl. J. Med. 346, 645-652.
34. Sawyers, C.L., et al. (2002) Glivec™ (imatinib mesylate) induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase II study. Blood 99, 3530-39.
35. Drexler, H.G., Gignac, S.M., von Wasielewski, R., Werner, M. and Dirks, W.G. (2000) Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia 14, 1533-1559.
36. Schlessinger, J. (2000) Cell signaling by receptor tyrosine kinases. Cell 103, 211-225.
37. Baloh, R.H., Enomoto, H., Johnson, E.M., Jr., and Milbrandt, J. (2000) The GDNF family ligands and receptors - implications for neural development. Curr. Opin. Neurobiol. 10, 103-110.
38. Santoro, M., Melillo, R.M., Carlomagno, F., Fusco, A., and Vecchio, G. (2002) Molecular mechanisms of RET activation in human cancer. Ann. N. Y. Acad. Sci. 963, 116-121.
39. Stirewalt, D.L. and Radich, J.P. (2003) The role of FLT3 inhaematopoietic malignancies. Nat. Rev. Cancer 3, 650-665.
40. Griffith, J., Black, J., Faerman, C., Swenson, L., Wynn, M., Lu, F., Lippke, J. and Saxena, K. (2004) The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol. Cell 13, 169-178.

Parole Chiave

PROTEINCHINASI; INIBITORI; FOSFORILAZIONE PROTEICA; LINFOMI; PROTEINE DI FUSIONE ONCOGENICHE; PROTEINCHINASI CK2; TIROSINE CHINASI; CRISTALLOGRAFIA; SINTESI ORGANICA